BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 36377973)

  • 1. BRUIN MCL-321: phase III study of pirtobrutinib versus investigator choice of BTK inhibitor in BTK inhibitor naive mantle cell lymphoma.
    Eyre TA; Shah NN; Dreyling M; Jurczak W; Wang Y; Cheah CY; Song Y; Gandhi M; Chay C; Sharman J; Andorsky DJ; Messersmith HM; Ruppert AS; Muthig VA; Ito R; Wang ML
    Future Oncol; 2022 Nov; 18(36):3961-3969. PubMed ID: 36377973
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pirtobrutinib: A novel non-covalent BTK inhibitor for the treatment of adults with relapsed/refractory mantle cell lymphoma.
    Davis DD; Ohana Z; Pham HM
    J Oncol Pharm Pract; 2024 Jan; 30(1):182-188. PubMed ID: 38043933
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study.
    Mato AR; Shah NN; Jurczak W; Cheah CY; Pagel JM; Woyach JA; Fakhri B; Eyre TA; Lamanna N; Patel MR; Alencar A; Lech-Maranda E; Wierda WG; Coombs CC; Gerson JN; Ghia P; Le Gouill S; Lewis DJ; Sundaram S; Cohen JB; Flinn IW; Tam CS; Barve MA; Kuss B; Taylor J; Abdel-Wahab O; Schuster SJ; Palomba ML; Lewis KL; Roeker LE; Davids MS; Tan XN; Fenske TS; Wallin J; Tsai DE; Ku NC; Zhu E; Chen J; Yin M; Nair B; Ebata K; Marella N; Brown JR; Wang M
    Lancet; 2021 Mar; 397(10277):892-901. PubMed ID: 33676628
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pirtobrutinib in Covalent Bruton Tyrosine Kinase Inhibitor Pretreated Mantle-Cell Lymphoma.
    Wang ML; Jurczak W; Zinzani PL; Eyre TA; Cheah CY; Ujjani CS; Koh Y; Izutsu K; Gerson JN; Flinn I; Tessoulin B; Alencar AJ; Ma S; Lewis D; Lech-Maranda E; Rhodes J; Patel K; Maddocks K; Lamanna N; Wang Y; Tam CS; Munir T; Nagai H; Hernandez-Ilizaliturri F; Kumar A; Fenske TS; Seymour JF; Zelenetz AD; Nair B; Tsai DE; Balbas M; Walgren RA; Abada P; Wang C; Zhao J; Mato AR; Shah NN
    J Clin Oncol; 2023 Aug; 41(24):3988-3997. PubMed ID: 37192437
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Matching-Adjusted Indirect Comparison of Brexucabtagene Autoleucel (ZUMA-2) and Pirtobrutinib (BRUIN) in Patients with Relapsed/Refractory Mantle Cell Lymphoma Previously Treated with a Covalent Bruton Tyrosine Kinase Inhibitor.
    Salles G; Chen JMH; Zhang I; Kerbauy F; Wu JJ; Wade SW; Nunes A; Feng C; Kloos I; Peng W; Snider JT; Maciel D; Chan K; Keeping S; Shah B
    Adv Ther; 2024 May; 41(5):1938-1952. PubMed ID: 38494543
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pirtobrutinib: First Non-covalent Tyrosine Kinase Inhibitor for Treating Relapsed or Refractory Mantle Cell Lymphoma in Adults.
    De SK
    Curr Med Chem; 2023 Oct; ():. PubMed ID: 37818564
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Zanubrutinib in lymphoproliferative disorders: a comprehensive review.
    Muñoz J; Wang Y; Jain P; Wang M
    Ther Adv Hematol; 2022; 13():20406207221093980. PubMed ID: 35651781
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia.
    Mato AR; Woyach JA; Brown JR; Ghia P; Patel K; Eyre TA; Munir T; Lech-Maranda E; Lamanna N; Tam CS; Shah NN; Coombs CC; Ujjani CS; Fakhri B; Cheah CY; Patel MR; Alencar AJ; Cohen JB; Gerson JN; Flinn IW; Ma S; Jagadeesh D; Rhodes JM; Hernandez-Ilizaliturri F; Zinzani PL; Seymour JF; Balbas M; Nair B; Abada P; Wang C; Ruppert AS; Wang D; Tsai DE; Wierda WG; Jurczak W
    N Engl J Med; 2023 Jul; 389(1):33-44. PubMed ID: 37407001
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FDA Approval Summary: Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma.
    Telaraja D; Kasamon YL; Collazo JS; Leong R; Wang K; Li P; Dahmane E; Yang Y; Earp J; Grimstein M; Rodriguez LR; Theoret MR; Gormley NJ
    Clin Cancer Res; 2024 Jan; 30(1):17-22. PubMed ID: 37624619
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Review of Bruton tyrosine kinase inhibitors for the treatment of relapsed or refractory mantle cell lymphoma.
    Owen C; Berinstein NL; Christofides A; Sehn LH
    Curr Oncol; 2019 Apr; 26(2):e233-e240. PubMed ID: 31043832
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pirtobrutinib: a new hope for patients with BTK inhibitor-refractory lymphoproliferative disorders.
    Thompson PA; Tam CS
    Blood; 2023 Jun; 141(26):3137-3142. PubMed ID: 37156004
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical characterization of pirtobrutinib, a highly selective, noncovalent (reversible) BTK inhibitor.
    Gomez EB; Ebata K; Randeria HS; Rosendahl MS; Cedervall EP; Morales TH; Hanson LM; Brown NE; Gong X; Stephens J; Wu W; Lippincott I; Ku KS; Walgren RA; Abada PB; Ballard JA; Allerston CK; Brandhuber BJ
    Blood; 2023 Jul; 142(1):62-72. PubMed ID: 36796019
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pirtobrutinib: First Approval.
    Keam SJ
    Drugs; 2023 Apr; 83(6):547-553. PubMed ID: 37004673
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Distinct BTK inhibitors differentially induce apoptosis but similarly suppress chemotaxis and lipid accumulation in mantle cell lymphoma.
    Liu Z; Liu J; Zhang T; Li L; Zhang S; Jia H; Xia Y; Shi M; Zhang J; Yue S; Chen X; Yu J
    BMC Cancer; 2021 Jun; 21(1):732. PubMed ID: 34174847
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting BTK in B Cell Malignancies: From Mode of Action to Resistance Mechanisms.
    Mouhssine S; Maher N; Matti BF; Alwan AF; Gaidano G
    Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542207
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pirtobrutinib: A New and Distinctive Treatment Option for B-Cell Malignancies.
    Schultze MD; Reeves DJ
    Ann Pharmacother; 2024 Jan; ():10600280231223737. PubMed ID: 38235739
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Pirtobrutinib in covalent BTK-inhibitor pre-treated relapsed/refractory (R/R) Mantle Cell Lymphoma].
    Fileni C; Sarkozy C
    Bull Cancer; 2023 Oct; 110(10):988-990. PubMed ID: 37658026
    [No Abstract]   [Full Text] [Related]  

  • 18. Bruton Tyrosine Kinase Inhibitors in B-Cell Malignancies: Their Use and Differential Features.
    Shirley M
    Target Oncol; 2022 Jan; 17(1):69-84. PubMed ID: 34905129
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-Covalent Bruton's Tyrosine Kinase Inhibitors in the Treatment of Chronic Lymphocytic Leukemia.
    Montoya S; Thompson MC
    Cancers (Basel); 2023 Jul; 15(14):. PubMed ID: 37509309
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cotargeting of BTK and MALT1 overcomes resistance to BTK inhibitors in mantle cell lymphoma.
    Jiang VC; Liu Y; Lian J; Huang S; Jordan A; Cai Q; Lin R; Yan F; McIntosh J; Li Y; Che Y; Chen Z; Vargas J; Badillo M; Bigcal JN; Lee HH; Wang W; Yao Y; Nie L; Flowers CR; Wang M
    J Clin Invest; 2023 Feb; 133(3):. PubMed ID: 36719376
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.